Home › FDA Approves Perjeta For Neoadjuvant Breast Cancer Treatment
 

Keywords :   


FDA Approves Perjeta For Neoadjuvant Breast Cancer Treatment

2013-10-02 06:33:29| drugdiscoveryonline News Articles

The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer

Tags: treatment cancer breast breast cancer

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
09.11Atlantic Tropical Weather Outlook
09.11Eastern North Pacific Tropical Weather Outlook
08.11Hurricane Rafael Graphics
08.11Hurricane Rafael Wind Speed Probabilities Number 22
08.11Hurricane Rafael Forecast Advisory Number 22
08.11Hurricane Rafael Public Advisory Number 22
08.11Summary for Hurricane Rafael (AT3/AL182024)
08.11Trump tariffs could cost UK 22bn of exports
More »